#non-Hodgkin's lymphoma

Women with lymphoma who received treatment in the afternoon had lower relapse and mortality rates than those treated earlier in the day.

The Dana-Farber led ALPINE trial looked at the drug in relapsed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Immunotherapy leads the way, along with promising breakthroughs for treating leukemia and multiple myeloma.

However, lung cancer incidence among HIV-positive people has fallen over the past two decades.

As the new editor-in-chief of Cancer Health, Trent Straube is honored to amplify stories of survivors, families, advocates and more.

A new study finds that Medicaid expansion increases survival and reduces health disparities for newly diagnosed patients with cancer.

Researchers are examining opportunities for immune-modulating approaches to improve outcomes and reduce side effects.

The popular weed killer has been linked to tens of thousands of cases of non–Hodgkin lymphoma.

Better treatments for hepatitis B and C and a lack of such advances for fatty liver or alcoholic liver disease are driving outcomes.

Monsanto’s herbicide faces thousands of such claims.

A recent study found that from 1995 to 2009, 10 percent of all deaths among a large cohort of people on HIV treatment were cancer-related.

Meet one childhood cancer survivor and his mom who are eager to share their stories of hope and courage.

Low CD4 cells are not the only risk factor for non-Hodgkin’s lymphoma (NHL) in people living with HIV.